Detroit has a saying that cuts straight to the bone: we don’t have healthcare in this country, we have sick care. And right now, sick care is getting more expensive, more complicated, and harder to access for the people who need it most.
Health insurance premiums are doubling for some metro Detroit residents after Republicans failed to extend the Affordable Care Act subsidies, squeezing working families who don’t qualify for Medicaid but can’t absorb $800-a-month premium bills either. That’s not a national abstraction. That’s someone in Brightmoor rationing insulin. That’s a Hamtramck family skipping the pediatrician because the copay doesn’t fit the week’s budget.
The argument gaining traction among health policy advocates is direct: the federal government should be driving drug development, not leaving that work to pharmaceutical corporations whose first obligation is to shareholders, not patients.
It’s a structural critique, not a talking point.
Right now, the drug development pipeline works like this. The National Institutes of Health funds enormous amounts of basic research using public tax dollars, researchers make discoveries, and then private companies license those discoveries, run clinical trials, and set prices with almost no public input. The company that didn’t fund the foundational science gets to decide what a lifesaving drug costs. That’s the deal Americans have lived with for decades, and by most public health measures, it isn’t working.
The United States spends more per capita on healthcare than any other wealthy nation while producing worse outcomes on life expectancy and chronic disease management, according to data tracked by the Commonwealth Fund. Detroit knows this intimately. Wayne County’s health outcomes trail national averages on cardiovascular disease, diabetes, and maternal mortality, conditions where treatment exists but cost puts it out of reach for too many residents.
Advocates arguing for a federal drug development role point out that a public model could prioritize diseases based on public health need rather than profit margin. Rare diseases affecting small populations, antibiotic-resistant infections that don’t generate the revenue of a daily cholesterol pill, mental health medications, all of these areas suffer from chronic underinvestment by private industry because the math doesn’t pencil out for Wall Street.
The counterargument from industry has always been that private competition drives innovation faster than government bureaucracy ever could. That case has gotten harder to make as drug prices climbed through the 2010s and 2020s with no corresponding acceleration in cures for the diseases killing the most Americans.
As Metro Times has reported on this debate, the frame coming out of Detroit is personal. People here don’t experience pharmaceutical policy through an economics textbook. They experience it in the Walgreens line when the pharmacist says the price changed and they can’t afford it today.
The current federal direction isn’t moving toward more public investment in drug development. The Trump administration has cut funding at NIH and pushed deregulation as the primary health policy lever, a posture that critics say hands more control to the same corporations whose pricing decisions already pushed medications beyond reach for millions.
None of this is theoretical for southeast Michigan. Detroit’s uninsured rate has historically run higher than the national average, and coverage losses tied to ACA subsidy changes hit communities in the city harder than suburbs where employer-sponsored insurance is more common. When access narrows at the coverage level and again at the pharmacy counter, the damage compounds fast.
The practical case for federal drug development doesn’t require an ideological leap. It requires looking at what public investment already produces and asking why the public doesn’t capture more of the benefit. NIH-funded research contributed to the development of almost every one of the 210 drugs approved by the FDA between 2010 and 2019, according to a study published in the Proceedings of the National Academy of Sciences. The funding is already public. The question is who controls what happens next.
Detroit’s healthcare advocates aren’t waiting for a national policy shift to make that argument. They’re making it at community health fairs, at council meetings, in church basements on the east side. The sick care system is failing enough people visibly enough that the structural conversation is no longer just for policy wonks. It’s a kitchen table conversation in a lot of zip codes around here, and it’s getting louder.
